Richard R. DeLuca Jr. - 05 May 2026 Form 4 Insider Report for Merck & Co., Inc. (MRK)

Reporting relationship: EVP&Pres, Merck Animal Heallth
Issuer ticker: MRK
Reported as of: 05 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 May 2026, 11:56:43 UTC
Prior SEC filing: 01 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Kelly E. W. Grez as Attorney-in-Fact for Richard R. DeLuca, Jr.

Key filing fact

Richard R. DeLuca Jr. filed Form 4 for Merck & Co., Inc. (MRK) on 07 May 2026.

Key facts

This page summarizes Richard R. DeLuca Jr.'s Form 4 filing for Merck & Co., Inc. (MRK).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 07 May 2026, 11:56.

Change

Previous filing in this sequence was filed on 01 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001421339 Primary reporting owner

DeLuca Richard R.

Relationship: EVP&Pres, Merck Animal Heallth
Address: MERCK & CO., INC., 126 EAST LINCOLN AVENUE, RAHWAY
Signature: /s/ Kelly E. W. Grez as Attorney-in-Fact for Richard R. DeLuca, Jr.
Signature date: 07 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MRK holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 161,537
Date: 05 May 2026
Ownership: Direct

MRK holding

Common Stock - 401(k) Plan

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,321
Date: 05 May 2026
Ownership: By 401(k)

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MRK transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares: +11,931
Change %
Price: $0.000000^*
Shares after: 11,931
Date: 05 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,931
Exercise price
Footnotes: F1, F2

MRK transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +34,924
Change %
Price: $0.000000^*
Shares after: 34,924
Date: 05 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 34,924
Exercise price: $113.15
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

Footnote F2

These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029.

Footnote F3

The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029.